Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email [email protected] in the first instance.

 Information  X 
Enter a valid email address

Proteome Sciences (PRM)

  Print      Mail a friend

Monday 12 February, 2018

Proteome Sciences

Trading Update

RNS Number : 5129E
Proteome Sciences PLC
12 February 2018

                                                                                    12 February 2018


Proteome Sciences plc

("Proteome Sciences" or the "Company")


Trading Update

The Company today provides a trading update for the 12 months ending 31 December 2017. 

Driven by strong sales of our TMT® reagents and the associated royalties, unaudited revenues for the full year increased by 18% to approximately £3.2m (2016: £2.7m).  Costs of £5.1m were 5% lower than the previous year (2016: £5.4m) reflecting the early impact of consolidation and restructuring.  The Company anticipates a reduced loss before tax of approximately £2.1m (2016: £2.9m).  

While there has been significant volatility in foreign exchanges during the course of the year, affecting non-sterling denominated revenues as well as those costs associated with our primary facility in Frankfurt, the overall effect on EBITDA was neutral.

Cash reserves at the year-end were approximately £0.8m despite the delayed payment of a material 2016 R&D tax credit, receipt of which is now expected during the first quarter of 2018.  In addition, the Board is pleased with a strengthening order book carried through from late 2017. 

The Directors look forward to updating shareholders further on the Company's performance, and on the outlook for 2018, at the time of the full year results

Appointment of Sales Agent in Europe

A sales agent model has now been introduced in Europe, similar to that initiated in the US last summer.  Cenibra GmbH signed a contract covering German speaking countries and, following training in January, has agreed a selling plan for immediate implementation.  We are confident that this engagement will quickly increase our access to a broader client base in Europe and complete the fundamental change necessary for the commercialisation of our services business.

Jeremy Haigh, Chief Executive of Proteome Sciences, commented:

"While progress was slower than we would have wished during 2017, particularly on the services side of the business where early adoption has been challenging, this is not surprising given the scale of change undertaken by the Company in the first half of the year.  However, with the benefits of a leaner organisation, a new model for commercial engagement now fully deployed in both our principal operating territories and the reassurance of robust and increasing demand for our TMT® reagents, we have the platform necessary to realise the full value of our available proteomic technologiesFollowing fundamental changes to our services business we are encouraged by stronger performance in the fourth quarter of 2017 and the order book moving into 2018.  It is now possible to consider the range of options available to a company with our ambition; I look forward to doing this and to providing further updates throughout the course of the year."



For further information:


Proteome Sciences plc

Jeremy Haigh, Chief Executive Officer

Tel: +44 (0)20 7043 2116

Ian Pike, Chief Scientific Officer

finnCap Limited (Nominated Adviser & Broker) 

Geoff Nash/James Thompson

Tony Quirke (Broking)

Tel: +44 (0)20 7220 0500




IFC Advisory (Financial PR and IR)



Tim Metcalfe/Graham Herring/Miles Nolan

Tel: +44 (0)20 3934 6630




About Proteome Sciences plc. (


Proteome Sciences is a leader in applied proteomics offering high sensitivity, proprietary technologies and workflows for mapping cell signalling pathways (SysQuant®) and for the discovery, validation and assay development of protein biomarkers (TMTcalibrator). The company has its headquarters in London, UK, with laboratory facilities in Frankfurt, Germany from where the PS Biomarker Services division provides outsourced proteomics services and proprietary biomarker assays to biopharmaceutical and diagnostics companies and to academia.


Proteome Sciences has patented several novel protein biomarkers for diagnostic and treatment applications in important areas of human therapeutics such as cancer, stroke and Alzheimer's disease, and these are available for license.


This announcement contains inside information for the purpose of Article 7 of EU Regulation 596/2014

This information is provided by RNS
The company news service from the London Stock Exchange

a d v e r t i s e m e n t